Key points are not available for this paper at this time.
Patients with low-penetrance NLRP3 variants display a distinct clinical phenotype and an intermediate biologic phenotype, including IL-1β and non-IL-1β-mediated inflammatory pathway activation.
Kuemmerle‐Deschner et al. (Mon,) studied this question.